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Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by the degeneration of the dopaminergic neurons in
the substantia nigra pars compacta (SNpc). Activation of themixed lineage kinase and c-Jun N-terminal kinase (JNK) has been reported
in models of PD. Our focus was to discern whether distinct pathways were activated in cell-specific manner within the SNpc. We now
demonstrate the selective phosphorylation of p38MAPkinasewithin the dopaminergic neurons,whereas JNKactivation occurs predom-
inantly in the microglia. p38 activation results in downstream phosphorylation of p53 and increased p53 mediated transcription of Bax
and Puma in the ventral midbrain. Treatment with p38 inhibitor, SB239063 protected primary dopaminergic neurons derived from
human progenitor cells fromMPPmediated cell death and prevented the downstream phosphorylation of p53 and its translocation to
the nucleus in vivo, in the ventral midbrain. The increased staining of phosphorylated p38 in the surviving neurons of SNpc in human
brain sections frompatientswithPDand inMPTP treatedmicebutnot in the ventral tegmental areaprovides further evidence suggesting
a role for p38 in the degeneration of dopaminergic neurons of SNpc. We thus demonstrate the cell specific activation of MAP kinase
pathwayswithin the SNpc afterMPTP treatment emphasizing the role ofmultiple signaling cascades in the pathogenesis andprogression
of thedisease. Selective inhibitorsofp38may therefore, helppreserve the survivingneurons inPDandslowdown thediseaseprogression.
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Introduction
Parkinson’s disease (PD) is a movement disorder characterized
by the selective loss of dopaminergic neurons of substantia nigra
pars compacta (SNpc) and their terminals in the striatum. The
mechanism underlying the selective vulnerability of SNpc neu-
rons is yet unclear although mitochondrial dysfunction seen as
complex I loss is recognized as a keyplayer in thepathogenesis of PD
(Mizuno et al., 1995;Olanow, 2007). Dysfunction of complex I seen
in brain,muscle andplatelets of Parkinson’s disease patients (Parker
et al., 1989) can generate reactive oxygen species (ROS) leading to
substantial oxidative stress (Mancuso et al., 2007).
ROS can activate several signaling pathways in cells including
those that regulate cell death. An important signaling pathway
that is activated by ROS is the mitogen-activated protein kinase
(MAPK) pathway. The family of MAP kinases comprises of ex-
tracellular signal-regulated kinases (ERKs) and stress-activated
protein kinases (SAPKs), c-Jun N-terminal kinases (JNKs) and
p38 kinases. JNK is phosphorylated in models of PD (Klintworth
et al., 2007; Saporito et al., 2000) and in the SNpc of PD patients
obtained at autopsy (Ferrer et al., 2001) and JNK inhibitors offer
neuroprotection in PD models. The downstream events after
JNK activation leading to apoptosis could potentially involve
both transcriptional and mitochondrial mechanisms. Together,
these studies show that JNK directly phosphorylates Bim leading
to activation of Bax, which translocates to the mitochondria fa-
cilitating cytochrome c release and apoptosis in animal model of
PD (Perier et al., 2007). Both transcriptional and post-
translational activation of Bax have been observed in SNpc of
MPTP treated mice (Duan et al., 2002) and PD patients (Hart-
mann et al., 2001), and Bax knock-out mice are protected from
MPTP toxicity (Vila et al., 2001; Perier et al., 2005). MPTP also
activates p53 which induces transcriptional upregulation of Bax
and p53 knock-out mice are also protected from MPTP toxicity
(Duan et al., 2002; Perier et al., 2007).
In light of these compelling observations, it is indeed surpris-
ing that CEP1347, an upstream inhibitor of JNK (which prevents
JNK activation through inhibition of mixed lineage kinases,
MLK) did not afford any neuroprotection in clinical trials per-
formed in early PD patients (Parkinson Study Group PRECEPT
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Investigators, 2007) although previous treatment with JNK in-
hibitor(s) offered neuroprotection in cultured cells (Wang et al.,
2004) and animal models of PD (Saporito et al., 1999).
Our focus was to discern whether distinct MAP kinases were
activated in a cell-specific manner within the SNpc and identify
their contribution to the demise of dopaminergic neurons. We
now demonstrate that there is selective phosphorylation of p38
MAP kinase in the SNpc neurons, whereas the activation of JNK
occurs predominantly in the microglia. Identification of cell-
selective activation of death signaling pathways in distinct cell
population could help in the development of specific inhibitors
for treatment as disease modifying agents in PD.
Materials andMethods
Materials.Antibodies to Bax (B-9,monoclonal), p38 (C-20, polyclonal,
p38), pJNK (G-7, monoclonal), and p53 (DO-1, monoclonal) were pur-
chased from Santa Cruz Biotechnology. Antibody to -tubulin was ob-
tained fromSigma-Aldrich. Antibody to pp53 (Ser15)was obtained from
Abcam. Antibodies to pp38 MAPK (Thr180/Tyr182), JNK and lamin
A/C were purchased from Cell Signaling Technology. Antibody to ty-
rosine hydroxylase was obtained from Chemicon. Anti-Histone H3 was
obtained fromUpstate. Antibodies to neuronal class III-tubulin (Tuj1)
and Iba1 were obtained from Covance and Wako Pure Chemical Indus-
tries, respectively. Vectastain-ABC Elite kit was purchased from Vector
Labs. p38 inhibitor, SB239063 was obtained from Calbiochem. In situ
Cell Death Detection Kit, TMR red kit was purchased from Roche. All
other chemicals and reagents were of analytical grade and were obtained
from Sigma-Aldrich or Qualigens.
Animals. All animal experiments were performed as per the institu-
tional guidelines for the use and care of animals. All efforts were made to
minimize animal suffering, to reduce the number of animals used and to
use alternatives to in vivo techniques if available. Male C57BL6J (2–3
months, 25–30 g) were obtained from Central Animal Research Facility
of National Brain Research Centre (NBRC). Male C57BL6J mice were
administered MPTP (30 mg/kg body weight/d, s.c.). Control animals
received saline alone. Animals were treated with a single dose of MPTP
and killed 1, 4, 12, and 24 h later. Some animals also received the above
dose of MPTP daily for 8 d and were killed 24 h after the last dose.
Animals had access to pelleted diet andwater ad libitum. At the end of the
experimental period, mice were anesthetized with ether and perfused
transcardially with ice-cold normal saline before decapitation. Ventral
midbrain and striatum were dissected as described earlier (Karunakaran
et al., 2007) and frozen in liquid nitrogen for immunoblotting. In some
experiments, animalswere perfused transcardiallywith buffered parafor-
maldehyde (4% w/v) and the brain was dissected out and processed for
immunohistochemistry. For examining the effect of p38 kinase inhibitor in
vivo, mice were divided into four groups. Two groups received the vehicle
DMSO (3% in normal saline; 100l) intrathecally and this was followed by
normal saline orMPTP (30mg/kg bodyweight; s.c.) 1 h later. The other two
groups received SB239063 (92 g dissolved in 100 l of 3% DMSO) intra-
thecally beforeMPTP or saline treatment.Mice were killed 12 h afterMPTP
treatment and the ventral midbrain was dissected out.
Processing of tissue. Tissue was homogenized in 0.25 M sucrose and
centrifuged at 1000  g for 10 min to obtain postnuclear supernatant.
The postnuclear supernatant was used for immunoblotting. In some
experiments the cytosol was isolated from the postnuclear supernatant
by centrifugation at 100,000  g for 1 h. Protein concentration was
estimated by a dye-binding method (Bradford, 1976). Nuclear extracts
were prepared as described (Korner et al., 1989).
Human brain samples. Brain tissue from male traffic accident victims
(control) and PD patients were obtained from the Human Brain Tissue
Repository of theNational Institute ofMentalHealth andNeurosciences,
Bangalore, India, in compliance with the ethical guidelines of the Gov-
ernment of India. Autopsy was performed after obtaining informed con-
sent from the next of kin and the protocol for use of autopsy tissue was
cleared by the institutional human ethics committee ofNational Institute
of Mental Health and Neurosciences, Bangalore and National Brain Re-
search Centre, Manesar. After autopsy, brains were washed in ice-cold
saline and substantia nigra was dissected out. The substantia nigra was
fixed in buffered formalin and processed for paraffin embedding.
Immunohistochemistry.Male C57BL6J mice were administeredMPTP
(30 mg/kg body weight/d, s.c.) once daily for 1 or 8 d. Control animals
received saline. Animals were anesthetized with ether 24 h after the last
injection and perfused transcardially with phosphate buffered saline
(PBS) followed by paraformaldehyde (4%, w/v) in PBS. Coronal sections
(30 m thick) were cut throughout the entire midbrain using a cryostat.
Immunostaining was visualized using FITC labeled secondary antibody
and counterstained with DAPI or HRP labeled secondary antibody fol-
lowed by staining with Nova Red.
Serial sections (5–7 m thick) were cut from paraffin embedded au-
topsy tissue from human brain. Sections were dewaxed, hydrated in
graded alcohol and PBS (10 mM, pH 7.4) and processed for immunohis-
tochemical staining in a similar manner as described above. Additional
treatment with hydrogen peroxide followed by potassium permanga-
nate/oxalic acid was performed to avoid interference caused by lipofuch-
sin (Barden, 1984; Schnell et al., 1999). Negative controls, wherein the
primary antibody was omitted were run along with the samples and
processed and photographed under the same conditions.
Immunoblotting. The postnuclear supernatant prepared from ventral
midbrain or striatum (20 g of protein) of vehicle and MPTP treated
mice were resolved on 10% SDS polyacrylamide gel. Proteins were trans-
ferred to nitrocellulosemembranes (Towbin et al., 1979), incubated with
primary antibody (1:1000) followed by secondary antibody (1:2000) la-
beled with alkaline phosphatase or secondary antibody (1:5000) labeled
with horseradish peroxidase. Immunostained bands were detected using
nitroblue tetrazolium and 5-bromo 4-chloro 3-indolyl phosphate as
chromogens (Roche) or using chemiluminescence kit (ECL, Amersham
Pharmacia Biotech). Blots were normalized with -tubulin, glyceralde-
hyde 3-phosphate dehydrogenase or lamin/histone as appropriate.
Quantitative real-time PCR. Total RNA was isolated frommouse ven-
tralmidbrain and cDNAwas synthesized from1g of total RNAbyusing
random hexamers. Real-time PCR was performed using Power SYBR
Green PCR Master Mix from Applied Biosystems according to the
manufacturer’s instructions. The sequences of the primers used were:
forward 5-CCACCTGAGTTCGCAGCTCAA-3, reverse 5-GTTGAGCA-
CACTCGTCCTTCAA-3 forNoxaandforward5-ACGACCTCAACGCA-
CAGTACG-3, reverse 5-TGGGTAAGGGCAGGAGTCC-3 for Puma.
All reactions were performed in triplicate and negative controls contained
no template DNA. The PCR conditions were: 95°C for 10 min, followed by
40 cycles of 95°C for 20 s, 67°C for 30 s and 72°C for 40 s. We used 18S
rRNA as an endogenous control for normalization. To verify that the
primer pair produced only a single product, a dissociation protocol was
added after thermocycling, determining dissociation of the PCR products
from 60°C to 95°C. Data were analyzed using the comparative threshold
cycle (Ct) method.
Studies with primary human CNS progenitor cells. Human CNS pro-
genitor cell cultures were prepared from 8- to 12-week-old embryos
obtained from electivemedical termination of first trimester pregnancies
performed at the local hospital after informed consent as per the ap-
proved protocol of the institutional human ethics committee in compli-
ance with the recommendations of the Indian Council of Medical Re-
search, Government of India. Primary cultures of human CNS
progenitor cells were prepared and cultured as monolayers on poly-D-
lysine coated chamber slides in serum-free neurobasal medium and neu-
rons were derived from them as described previously (Mishra et al.,
2008). Neuronal differentiation involved changing the growth factors in
the progenitor media to brain-derived neurotrophic factor (BDNF, 10
ng/ml) and platelet-derived growth factor (PDGF)-A/B (10 ng/ml) for 3
weeks. Almost 90% cells were positive for neuronal marker, Tuj-1. Cells
were seeded in 8 well chamber slides to a total count of 10,000 cells per
well and were immunostained for Tuj-1, glial fibrillary acidic protein
(GFAP) and tyrosine hydroxylase (TH) after fixation with 4% PFA. Cells
were treated with p38/JNK MAP kinase inhibitor (SB239063, 1 M;
SP600125, 5 M) or p53 inhibitor, pifithrin- (250 nM) 60 min before
treatment with MPP (10 M) or vehicle for 24 h. Cells were then
washed with PBS and fixed with 4% paraformaldehyde and immuno-
stained for p53. Finally the cells were mounted in medium containing
Karunakaran et al. • p38 MAPK in Parkinson’s Disease J. Neurosci., November 19, 2008 • 28(47):12500–12509 • 12501
propidium iodide (PI) and visualized under fluorescence microscope. In
some experiments the cell deathwas assessed using terminal deoxynucleoti-
dyl transferase mediated dUTP-biotin nick end-labeling (TUNEL) method
following manufacturer’s protocol. The cells were observed using fluores-
cence microscopy and both the TUNEL positive cells and DAPI stained
nuclei were counted in four independent experiments in each case. On av-
erage 300 cells were scored in four different fields for each sample.
Statistical analysis. Statistical analysis of the data were performed using
ANOVA or repeated measures of ANOVA followed by post hoc tests
(Student–Newman–Keuls or Dunnet’s test). Student’s t test or paired t
test were used when 2 groups were compared. Values of p  0.05 were
taken as being statistically significant.
Results
MPTP stimulates p38MAPK phosphorylation in substantia
nigra neurons
The phospho-MAPK signal was normalized to the total MAPK
signal in each sample to assess MAPK activation, as described
earlier (Guan et al., 2003; Sharma et al., 2006). In the ventral
midbrain sustained phosphorylation of p38 MAP kinase was ob-
served 12 and 24 h (3- to 3.8-fold) after a single dose of MPTP
(Fig. 1A). In the striatum, although increased phosphorylation of
p38 was seen after 12 h of MPTP treatment, total p38 levels (
p38) increased significantly such that the pp38/p38 ratio was not
significantly altered in the striatum (Fig. 1A).
We colocalized pp38 and tyrosine hydroxylase in the mid-
brain after acute and subchronic exposure to MPTP (Fig. 2A).
Increased phosphorylation of p38 was seen selectively in the
SNpc (Fig. 2B) as diffuse granular staining but not in the ventral
tegmental area (VTA) (Fig. 2C) after a single exposure or sub-
chronic exposure to MPTP for 8 d. Vehicle treated controls
showed sparse staining for pp38 (Fig. 2A–C). pp38 did not show
cell specific staining in the striatum after acute (Fig. 2D) or sub-
chronicMPTP treatment (Fig. 2D). However, the fiber terminals
Figure 1. A–D, MPTP-induced activation of p38 and JNK in the ventral midbrain and striatum. Animals were treated with a single dose of vehicle or MPTP and killed 1, 4, 12, and 24 h later or
treated with a daily dose of MPTP for 8 d and killed on the ninth day. Representative immunoblots from ventral midbrain (MB) and striatum (ST) of animals treated with saline (C) andMPTP (lanes
1, 4, 12, 24 h, 8 d) depicting (A) the levels of phospho-p38 (pp38) and p38 and (B) JNK54, JNK46, phospho-JNK54 (pJNK54), phospho-JNK46 (pJNK46) in theMB and ST afterMPTP treatment. C and
D depict the level of JNK54, JNK46, phospho-JNK54 (pJNK54), phospho-JNK46 (pJNK46) in the MB and ST after 8 d of MPTP treatment. -Tubulin levels were measured as loading controls.
Densitometric analysis of the immunoblots representing the relative intensity of the immunoreactive bands from MB (n 6) and ST (n 3) are shown below the respective blots. They are
representedas solid line for pJNK54and JNK54,whereaspJNK46and JNK46aredepictedasdotted lines inAandB. Activationofp38MAPKand JNK is indicatedby their respectivepMAPK/MAPK ratio.
The increase in ratio is expressedas fold increasewith respect to the control ratio (1.0). Values aremeanSD.Asterisks indicate values significantly different fromcorresponding control ( p0.05).
Repeated measures of ANOVA followed by Dunnet’s test was performed for A and B, whereas paired t test was performed for C and D.
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projecting toward the caudate and putamen showed increased
pp38 staining after MPTP treatment (Fig. 2D).
Phosphorylation of JNK is seen predominantly in microglia
in the substantia nigra
MPTP administration increased the levels of p46 and p54
phospho-JNK proteins by 1.6-fold in the ventral midbrain at
12–24 h (Fig. 1B). At early time periods, namely 1–4 h after a
single dose of MPTP, the ratio of phosphorylated to total JNK54
increased significantly. In the striatum, the activation of JNK 46
and 54 occurred soon after MPTP exposure (1 h) and was sus-
tained up to 24 h. Concomitant increase in the levels of the JNK
protein occurred and the ratio of pJNK/JNK was increased to
1.9-fold at 4–24 h for JNK46 and 1.6-fold at 4–12 h for JNK54
(Fig. 1B). The activation of JNK54 was attenuated by 24 h,
whereas JNK46 levels remained sustained. After exposure of
MPTP for 8 d the ratio of pJNK/JNK was increased for JNK 54
and 46 in the striatum (Fig. 1D) but not inmidbrain (Fig. 1C). In
the midbrain although the pJNK immunostaining persisted (Fig.
3A) and pJNK54 levels were increased as seen by immunoblot-
ting, we did not see increased ratio of pJNK54/JNK54 because of
increase in the level of total JNK 54. JNK46 was not activated in
midbrain (Fig. 1B,C).
Immunohistochemical localization of pJNK revealed that in
Figure 2. A–D, Activation of p38 in substantia nigra pars compacta (SNpc) and their terminals in the striatum after administration of MPTP to mice. Animals were treated with a single dose of
MPTPandkilled24h later or treatedwithadaily doseofMPTP for 8dandkilledon theninthday.A, Immunohistochemical colocalization revealed thepresenceof pp38 (green) in the somaof tyrosine
hydroxylase (TH) positive (red) SNpc neurons of the ventral midbrain after MPTP exposure. pp38 is present at low levels in the SNpc neurons of control animals while not detectable in ventral
tegmental area (VTA) neurons. After single dose for 24 h and 8 d of MPTP treatment, there was an increase in pp38 in the SNpc but not VTA (arrowhead). Negative control for colocalization of pp38
and TH in the ventral midbrain is depicted. Corresponding magnified images of the neurons in SNpc (B) and VTA (C) are depicted. D, Images from the striatum show pp38 in the nerve terminals
projecting toward the striatum in control, after a single dose and sub chronic exposure to MPTP. Scale bars: 25m; magnified images, 10m.
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Figure 3. Activation of JNK inmicroglial cells of the ventral midbrain and striatum after administration of MPTP tomice. Animals were treatedwith a single dose of MPTP and killed 24 h later or
a daily dose of MPTP for 8 d and killed on the ninth day. A, Immunohistochemical colocalization revealed the presence of pJNK (green) throughout the brain including tyrosine hydroxylase positive
neurons of the SNpc (red). Negative control for colocalization of pJNK and TH in the ventral midbrain is depicted. B, JNK activation was observed predominantly in the microglia in SNpc after 8 d of
MPTP treatment. C, pJNK (green) colocalized with Iba1(red) after single and 8 d of MPTP treatment. Negative control for colocalization of pJNK and Iba1in the ventral midbrain is depicted. D,
Magnified images depicting the colocalization of Iba1(red)with pJNK (green) after single dose and 8 d ofMPTP treatment. E, pp38 does not colocalizewith Iba1 afterMPTP (Figure legend continues.)
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vehicle treated control animals pJNK was discernible in the neu-
rons of substantia nigra (Fig. 3A,B). After MPTP exposure (sin-
gle dose or subchronic for 8 d) pJNK immunostaining increased
in the substantia nigra and the VTA (Fig. 3A,B) and the activa-
tion seemed to occur predominantly in microglial cells (Fig.
3C,D), which was in contrast to p38 activation that occurred in
neurons (Fig. 2B) but not in the microglia (Fig. 3E). pJNK colo-
calized with Iba 1 immunopositive cells after acute or subchronic
MPTP (Fig. 3C). In the striatum, pJNK immunostaining was
substantially increased after a single dose or subchronic exposure
toMPTP (Fig. 3F,G). pJNK immunostaining in the neurons seen
in the vehicle-treated controls persisted after MPTP exposure;
however, in addition, extensive staining was seen in microglial
cells in the striatum and midbrain (Fig. 3A–G).
Translocation of p53 to the nucleus after MPTP exposure
p53 can be phosphorylated by p38 MAP kinase, which facilitates
its accumulation in the nucleus. We, therefore, examined the
levels of both p53 and phospho-p53 (Ser15) in the nuclear com-
partment and found that they were increased indicating that in-
creased p53 mediated transcription could potentially take place
(Fig. 4A). MPTP also increased the levels of total p53 in the
postnuclear supernatant and specifically in the cytosol (Fig. 4B).
This was validated by immunohistochemistry wherein we ob-
served the translocation of p53 into the nucleus of the surviving
tyrosine hydroxylase positive neurons in SNpc after 8 d of MPTP
treatment (Fig. 4C). We then quantitated the mRNA levels of
Noxa and Puma, which are transcribed through p53 dependent
mechanism using qRT-PCR and found that a single dose of MPTP
resulted in significant increase in the levels of Puma but not Noxa
(Fig. 4D) 12h afterMPTP treatment. In addition, in thepostnuclear
supernatant, Bax, another target gene of p53 was also increased in a
sustainedmanner after a single dose ofMPTP (Fig. 4E).
MPTPmediated phosphorylation and translocation of p53 to
the nucleus is abolished by p38 inhibitor SB239063, in vivo
in mice
We examined the effect of pretreatment with SB239063, a selec-
tive inhibitor of p38 on the phosphorylation and translocation of
p53 to the nucleus afterMPTP exposure because p38 is known to
phosphorylate and stabilize p53 (Shieh et al., 1997; Vitale et al.,
2008). Pretreatment with SB239063 attenuated MPTP mediated
phosphorylation of p38 MAP kinase as expected (Fig. 4F,G).
Further, the downstream phosphorylation and translocation of
p53 was also abolished (Fig. 4 I). p53 mediated transcription of
Bax was attenuated but not abolished (Fig. 4H) indicating that
transcription of Bax could occur through alternate pathways
(Vila et al., 2001; Melino et al., 2004).
p38 inhibitor and pifithrin- afford protection against MPP
induced cell death in primary neurons derived from human
CNS progenitor cells
Primary cultures of human CNS progenitor cells were differenti-
ated into neurons and characterized for the dopaminergic phe-
notype by studying the expression of tyrosine hydroxylase (TH)
and neuronal marker -III-tubulin (Tuj1) (supplemental Fig.
1A, available at www.jneurosci.org as supplemental material).
On average, 89.9% cells were found to be positive for Tuj1 and
87.7% cells were found to be positive for tyrosine hydroxylase
staining (supplemental Fig. 1B, available at www.jneurosci.org as
supplemental material). Glial population was negligible, only 2%
of the cells were found to be positive forGFAP (supplemental Fig.
1D, available at www.jneurosci.org as supplemental material).
Cells were responsive toMPPmediated toxicity as examined by
TUNEL assay and dose-dependent increase in TUNEL positive
neurons was observed after exposure to increasing concentration
of MPP(supplemental Fig. 1E, available at www.jneurosci.org
as supplemental material). Both p38 inhibitor SB239063 (1 M)
(Fig. 5A) and p53 inhibitor pifithrin- (250 nM) (Fig. 5B) af-
forded complete protection against MPPmediated cell death.
MPPmediated nuclear translocation of p53 is abolished by
p38 inhibitor but not by JNK inhibitor
p53 is normally localized in the cytoplasm of primary neurons
derived from the human CNS progenitor cells (Fig. 5C). Expo-
sure to MPP (10 M) for 24 h caused nuclear translocation of
p53, which was prevented by pretreating the cells with p38 inhib-
itor, SB239063 (Fig. 5C), indicating the role of p38 in the trans-
location of p53. However, pretreatment of cells with JNK inhib-
itor, SP600125 attenuated the nuclear translocation of p53
minimally (Fig. 5D).
pp38 and pJNK in the substantia nigra of PD patients
Phospho-p38 and p-JNK are expressed in tyrosine hydroxylase
positive neurons of human substantia nigra (Fig. 6A,B). In the
control brain from traffic accident victims both pp38 and pJNK
immunostaining appeared to co localize within the tyrosine hy-
droxylase positive neurons. In PDpatients, the surviving neurons
from substantia nigra appeared shrunkenwith decreased tyrosine
hydroxylase immunostaining (Fig. 6A,B) and pp38 immuno-
staining was very prominent throughout the surviving tyrosine
hydroxylase positive neuron (Fig. 6A). In PD brains, pJNK im-
munostaining was not evident in the neuronal cells in contrast to
control (Fig. 6B); however, pJNK positive cells colocalized with
Iba 1 positive glia indicating an enhanced gliosis in PD brains
(Fig. 6C).
Discussion
p53 knock-out mice or mice pretreated with pfithrin, a p53 in-
hibitor are protected from dopaminergic cell death in SNpc after
MPTP (Trimmer. et al. 1996; Duan et al., 2002; Perier et al.,
2007). However, the upstream signaling pathways have not been
clearly defined.
The failure of the clinical trials using the JNK inhibitor
CEP1347 that does not affect ERK1/2 or p38 (Gallo and Johnson,
2002) raises the question about the role of JNK in the demise of
dopaminergic cells in SNpc. By blocking mixed lineage kinases
(MLK) of MAPKKK superfamily, CEP1347 is also known to
modulate the microglial activation of JNK/p38 under certain
stressful conditions (Lund et al., 2005). However, by only inhib-
iting theMLK family, the capability of otherMAPKKK to activate
p38 andMAPKK-independent activation of p38may still be pre-
served (Ge et al., 2002).We now report that selective activation of
p38 occurs in the dopaminergic neurons of SNpc in mice treated
with MPTP, whereas JNK phosphorylation is predominant in
microglia. Thus, the partial protection seen with CEP1347 in
animal models of PD could be due to its effect on microglia
mediated inflammatory response.
4
(Figure legend continued.) treatment. F, JNK activation was also observed specifically in micro-
glia in the striatum after single dose and 8 d of MPTP treatment. The magnified representative
images of cells indicated by arrowheads in F is depicted in G (first column). G, Change in
morphology of cells positive for pJNK to microglial morphology in the ventral midbrain after
MPTP treatment is also depicted. Neuron specific staining of pJNK is seen in the control section.
Scale bars: 25m; magnified images, 10m.
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To discern whether the activation of p38 was indeed linked to
the demise of the neurons, we examined the effect of p38 inhibi-
tor on MPP mediated toxicity, both in vitro in dopaminergic
neurons derived from human neural progenitor cells (Fig. 5A)
and in vivo, in mice (Fig. 4). We observed that p38 inhibitor;
SB239063, which inhibits both p38  and , prevented the trans-
location of p53 to the nucleus and afforded complete protection
against cell death, in vitro. In vivo, in the ventral midbrain, treat-
ment with p38 inhibitor prevented the downstream phosphory-
lation of p53 and its translocation to the nucleus. p38 inhibitor
SB239063 does not cross the blood brain barrier (Cao et al.,
2007), and therefore we administered it intrathecally.
p38 is known to phosphorylate p53. This post-translational
modification facilitates p53 accumulation in the nucleus (Shieh
et al., 1997; Vitale et al., 2008). Phosphorylation of p53 within or
close to the N-terminal MDM2 binding domain, i.e., at Ser15
increases the stability of p53 by interfering with its ability to bind
MDM2 and by decreasing ubiquitin-dependent degradation
(Shieh et al., 1997). We saw increased phosphorylation of p53 in
the nuclear compartment of ventral midbrain of mice treated
with MPTP, which was abolished by pretreatment with p38 in-
hibitor (Fig. 4 I). Thus, our results point to the selective activation
of p38 in the neurons of SNpc and its role in the downstream
phosphorylation of p53 leading to increased p53 mediated tran-
scription of Bax andPuma, but notNoxa. It needs to be examined
whether other targets of p53 are transcriptionally activated in
Figure4. MPTPadministration up-regulates p53 and induces p53mediated transactivation, in vivo. Animalswere treatedwith a single dose of vehicle orMPTPand killed 12 and24h later orwith
a daily dose of MPTP for 8 d and killed on the ninth day. A, pp53 (Ser15) accumulates in the nucleus 12 h after a single dose of MPTP and after subchronic exposure to MPTP for 8 d. Representative
immunoblots of nuclear p53 and phospho-p53 Ser15 with their densitometric analyses are depicted. Values are mean SD (n 7 animals). B, Representative immunoblot of extranuclear and
cytosolic p53 in ventralmidbrain (MB) and densitometric analyses of the post nuclear supernatant (PNS) and cytosolic p53 show the upregulation afterMPTP exposure. Values aremean SD (n
6 animals). C, Quantitative assessment of the expression of Noxa and Puma in ventral midbrain after MPTP treatment. qRT-PCR analysis using mouse ventral midbrain RNA shows relatively higher
expression of Noxa and Puma in mouse ventral midbrain after MPTP treatment for 12 h. All samples were normalized using 18S rRNA expression. Values are mean SD (n 6 animals). D,
Representative immunoblot for Bax from ventral midbrain (MB; n 5) of animals and densitometric analyses are shown. E, Animals were treatedwith a single dose of vehicle (3%DMSO) orMPTP
and killed 12 h later. Some animals also received a single dose of SB239063 intrathecally. E–G, Representative blots from ventral midbrain of animals treated with DMSO (lane 1), MPTP (lane 2),
SB239063 (lane 3), and SB239063 MPTP (lane 4) depicting the protein levels of phospho-p38, p38, and Bax (G) in the extranuclear compartment and pp53 Ser15 and p53 (F ) in the nuclear
compartment as determined by immunoblot are presented. pp38/p38 ratio represents p38 activation in ventral midbrain. Densitometric analysis of the immunoblots representing the relative
intensity of the immunoreactive bands are shown. Values are mean SD (n 4 animals).-Tubulin levels were measured as loading control for extranuclear compartment and lamin/histone
levelsweremeasured as loading control for nuclear compartment. Asterisks indicate values significantly different from corresponding control ( p 0.05). Statistical analysis using t test forA–E and
repeated measures of ANOVA followed by Dunnet’s test was performed for F–I.
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addition to the above. p38 inhibitor did
not abolish but attenuated the increase in
Bax levels (Fig. 4H). This indicates that
transcription of Bax can occur through al-
ternate pathways also (Vila et al., 2001;
Melino et al., 2004).
MK2 is a downstream target of p38 and
MK2 knock-out mice are protected from
MPTP toxicity (Thomas et al., 2008). This
has been attributed to the attenuation of
inflammatory response mediated through
p38 in themicroglia. The lack of coherence
between our observations could be due to
the fact that MK2 can be activated by up-
streamkinases other thanp38. Further, the
dosing paradigm for MPTP involved 4
doses in 24 h resulting in a massive insult
rather than the chronic toxicity paradigm
used in our experiments wherein a single
dose of MPTP was given daily for 8 d.
A protective role for p38 dependent
phosphorylation has been recently re-
ported (Plun-Favreau et al., 2007). Acti-
vated p38 phosphorylates HtrA2 (Omi) in
a PINK1 dependent manner which may
contribute to increased resistance of cells
to mitochondrial stress and further Omi
decreased in brain of PD patients. Al-
though the above report suggests an im-
portant function for p38 under normal
conditions in the mitochondria, it is to be
determinedwhether aberrant activation of
p38 as seen in the present study plays a
dysfunctional role within the mitochon-
dria also.
Increased pp38 immunostaining was
observed in the surviving tyrosine hydrox-
ylase positive neurons in the SNpc from
patients with Parkinson’s disease, which
was not observed in control brain from
traffic accident victims (Fig. 6A). Further,
pJNK staining seemed to be restricted to
the glial cells which colocalized with Iba1
staining indicating that JNK was phos-
Figure 5. p38 inhibitor confers protection against MPP mediated cell death by preventing p53 translocation into the
nucleus.A, Cells treatedwith SB239063 (1M) for 60min before exposure toMPP (10M) for 24 hwere protected fromMPP
mediated cell death. Scale bar, 200m. Cells were treated with either vehicle or SB239063 before the treatment with MPP,
quantification represents percentage of cells positive for TUNEL staining per total number of cells as represented by DAPI
4
staining. B, p53 inhibitor pifithrin- confers protection
against MPP mediated cell death. Cells treated with
pifithrin- (250 nM) for 60min before exposure toMPP (10
M) for 24hwerenot affectedbyMPPmediated cell death.
Scale bar, 200m. Cells were treated with either vehicle or
pifithrin- before the treatment with MPP, quantification
represents, percentage of cells positive for TUNEL staining per
total number of cells as represented by DAPI count. C, p53,
localized in the cytoplasm in primary neurons under control
condition translocated into the nucleus in response toMPP
exposure. The nuclear translocation was prevented by pre-
treating the cells with p38 inhibitor, SB239063. D, Nuclear
translocation was partially prevented by pretreating the cells
with JNK inhibitor, SP600125 (panel 4). Total number of cells
is representedbypropidium iodide (PI) staining. Data are rep-
resented as mean SD of four independent experiments.
Asterisks indicate values significantly different from controls
( p 0.05).
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phorylated in the microglia (Fig. 6C). The surviving neurons in
SNpc did not show predominant JNK activation (Fig. 6B). Al-
though the above observation is similar to that seen in theMPTP
mouse model, the data need to be interpreted carefully. The ani-
mal models do not replicate the human disease entirely. Further,
there is greater redundancy in human brain such that additional
pathways can be involved and the cross talk between the pathways
could potentially add to the complexity of the pathogenic pro-
cess. Nevertheless, the studies present herein point to the cell-
specific activation of death signaling cascade with similarities be-
tween the mouse model and the human disease.
Although the present study points to selective activation of
p38 within the dopaminergic neurons of SNpc and its role in p53
mediated cell death, the upstream mediators of p38 activation
remain to be identified. p38 is activated by theMAPKKs,which in
turn are activated by MAPKKK. We observed the activation of
pMKK6 (a MAPKK) in the ventral midbrain after MPTP expo-
sure (data not shown). Apoptosis signal regulating kinase (ASK1,
aMAPKKK) is activated in the ventralmidbrain however, it is yet
to be determined whether ASK1 activation (Karunakaran et al.,
2007) is indeed essential for the p38 activation. Potentially, the
presence of Iba1 positive activated microglia seen in the SNpc
signifying the inflammatory response (Fig. 3) could lead to gen-
eration of ROS, which in turn could activate ASK1 (Matsuzawa
and Ichijo, 2008; Noguchi et al., 2008), thus triggering the aber-
rant MAPK cascade resulting in p38 activation. However, the
evidence for the above needs to be established.
Earlier studies on the role of JNK activation have been per-
formed largely on cultured cells, whereas signaling, in vivo is
considerably more complex. For example, in cultured cells ex-
posed to MPP or paraquat, JNK is phosphorylated and JNK
inhibitors afford neuroprotection (Saporito et al., 1999; Wang et
al., 2004; Peng et al., 2004). However, in vivo cell-specific activa-
tion of signaling cascades ensues as seen in the present study with
p38 and JNK phosphorylation occurring in neuronal and glial
cells respectively. This difference may be attributed to the use of
cultured/primary cells; the toxin used and the dosage paradigm,
wherein chronic exposure involves administering several doses
on a single day versus a single dose for several days.
The dopaminergic neurons derived from the human neural
progenitors offer an excellent in vitro model for discerning mo-
lecularmechanisms after a neurotoxic insult. These primary neu-
rons express tyrosine hydroxylase and most of the Tuj1 positive
neurons also express tyrosine hydroxylase (supplemental Fig. 1A,
available at www.jneurosci.org as supplemental material) indi-
cating the predominant dopaminergic phenotype of these cells
(Mishra et al., 2008).
One of the compelling questions in understanding the patho-
genesis of neurodegenerative diseases in general and PD in par-
ticular is the vulnerability of selective cell population to neuro-
degeneration. The results described herein demonstrating the
selective activation of JNK and p38 in distinct cell populations
within the SNpc, namely the microglia and the dopaminergic
neurons, is a case in point (Figs. 2, 3). Identification of cell-
specific signaling pathways is vital for discovering and developing
therapeutic strategies that will go beyond global neuroprotection
and hold promise as diseasemodifying agents that can slow down
the degeneration of vulnerable cell population. It is to be deter-
mined whether selective inhibitors of p38 would help preserve
the surviving neurons in PD and slow down the disease progres-
sion, which the JNK inhibitor CEP1347 failed to do in human
trials (Parkinson Study Group PRECEPT Investigators, 2007).
We acknowledge that from a global perspective several mecha-
nisms could contribute to the neurodegeneration seen in diseases
Figure6. pp38andpJNK in the substantia nigra of PDpatients and schematic representation of the role of p38 inMPTPmediated toxicity.A, Immunohistochemical colocalization of phospho-p38
(green) in Tyrosine hydroxylase (red) positive neurons of control (traffic accident victims) and PD substantia nigra. B, Immunohistochemical colocalization of phospho-JNK (green) in Tyrosine
hydroxylase (red) positive neurons of control (traffic accident victims) and PD substantia nigra. C, pJNK immunopositive cells colocalizes with Iba-1 positive cells of substantia nigra (green) in PD
brain. Thebottomdepicts amagnifiedmicroglial cell indicating the colocalizationof pJNKwith Iba-1.Negative controlwasperformed for each set of experiment. Scale bars: (B,C) 10m; (A) 25m.
D, MPP is taken up by VMAT and concentrated in the synaptic vesicle generating ROS. MPP the toxic metabolite of MPTP causes increased production of ROS andmitochondrial dysfunction in
dopaminergic neurons by inhibiting complex I of the electron transport chain. Mitochondrial complex I inhibition further contributes to ROS generationwhich presumably activates p38MAP kinase
pathway. As a consequence, the downstream target p53 is phosphorylated. p53 subsequently translocates to the nucleus transcriptionally activating the expression of Puma, Noxa and Bax. Bax
translocates to themitochondria ultimately leading to cell death. Approaches aimed at inhibiting p38 activation can help terminate this cascade and attenuate MPTP-induced neurodegeneration.
DAT, Dopamine transporter; N, nucleus; VMAT, vesicular monoamine transporter.
12508 • J. Neurosci., November 19, 2008 • 28(47):12500–12509 Karunakaran et al. • p38 MAPK in Parkinson’s Disease
like PD, nevertheless the cell-specific activation of death signaling
cascade as seen in this study indicates that activation of p38 is
potentially an important contributor to the disease process lead-
ing to the degeneration of dopaminergic neurons of the SNpc in
PD. CEP1347 only attenuated but could not completely abolish
MPTPmediated degeneration of striatal dopaminergic nerve ter-
minals and cell bodies in the nigra (Saporito et al., 2000). In this
scenario, a combinatorial approach involving JNK and p38 in-
hibitors, which would target pathogenic mechanisms in distinct
cell populations would enhance neuroprotection in a region spe-
cific manner and beyond.
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